Eric Edwards, M.D., Ph.D.
I could not be more thrilled to be supporting this team of world-class research scientists as an advisor. Food allergies are deeply personal and I am confident the work by FASI will change the way food allergies are prevented, treated, and cured in the future.
Dr. Eric Edwards was previously co-founder of Kaléo, Inc., a pharmaceutical company in Richmond, Virginia. He is the co-inventor of multiple marketed products, including AUVI-Q, epinephrine auto-injector for the treatment of anaphylaxis. Dr. Edwards is named on over 215 issued and pending patent applications and is a published author of numerous scientific publications.
During his 16 years at Kaléo, he held several executive management positions including: Chief Science Officer, responsible for overall scientific strategy and all pharmaceutical development programs; Chief Medical Officer, responsible for developing a medical affairs team and capability while operationalizing the company’s clinical program strategy; and Vice President of Innovation, overseeing Kaleo’s research and development pipeline and overall product strategy.
After leaving Kaléo, Dr. Edwards began working with Dr. Frank Gupton on the challenges associated with drug shortages and drug pricing in the United States. Together, alongside their strategic partners, they have built a world-class team focused on solving these challenging problems, including the over-reliance on foreign manufacturers for our nation’s most essential generic medicines.
Dr. Edwards obtained his bachelor’s degree in biology, Ph.D. in the pharmaceutical sciences and Doctor of Medicine at Virginia Commonwealth University/Medical College of Virginia. He is also a food allergy patient and parent.